Vical touts animal study of vax adjuvant

Vical announced today that the company's Vaxfectin adjuvant significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Vical release